Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia
MILPITAS, Calif., April 25 (Bernama) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in the Asia Pacific region, marking a significant milestone in the device's global introduction. The procedures were successfully performed at Cardiac Vascular Sentral Kuala Lumpur Hospital in Kuala Lumpur by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD.
The LithiX™ HC-IVL device represents a novel mechanical approach to calcium modification in calcified coronary lesions, offering the benefits of intravascular lithotripsy using prior technologies without requiring an external energy source. Based on the Hertz Contact Stress principle, the device delivers precise mechanical amplification of force to achieve calcium fractures while minimizing unintended vessel trauma.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
5 hours ago
- Barnama
World Expo Water Shows Halted After Detection Of Legionella Bacteria
OSAKA, June 5 (Bernama-Kyodo) -- Water shows at the World Exposition in Osaka have been suspended through Friday after high levels of legionella bacteria were detected in seawater at the venue, Kyodo News Agency reported. Expo organisers said at a press conference on Thursday that the level of legionella detected in water from the Water Plaza in a test on Wednesday was 20 times higher than the allowable limit under their guidelines, prompting them to cancel shows from Wednesday. The shows' resumption depends on the results of measures they have implemented to improve water quality, including sanitisation, pipe cleaning and increased circulation of seawater around the area, they said.
Barnama
7 hours ago
- Barnama
TH Assigns Companions To 37 Ailing Pilgrims Under Peneman Initiative
From Nurliyana Farhah Ruslan ARAFAH, June 5 (Bernama) -- Lembaga Tabung Haji (TH) has assigned companions to selected 37 ailing Malaysian pilgrims not accompanied by their family members during the Masya'ir phase under its Program Prihatin Tetamu Ar-Rahman (PENEMAN). Minister in the Prime Minister's Department (Religious Affairs) Datuk Dr Mohd Na'im Mokhtar said the PENEMAN companionship initiative manifests TH's ongoing commitment to protecting the welfare of Malaysian pilgrims, particularly during wukuf, a defining moment of the haj journey at Arafah. "A staff member will accompany each physically challenged pilgrim. These companions will not only assist with physical needs such as using the restroom and mobility but also provide spiritual guidance and support," he said after visiting Malaysian pilgrims at their tents here today. Mohd Na'im explained that the selected pilgrims are elderly individuals as well as those facing difficulties in managing themselves and do not have family members to assist them throughout the pilgrimage. Mohd Na'im said the PENEMAN initiative involves 38 TH personnel, comprising 27 women and 11 men, tasked with providing dedicated care and assistance to each ailing pilgrim throughout the pilgrimage, particularly during their time in Arafah. "This year saw a slight decrease in the number of pilgrims participating in the PENEMAN initiative…compared to 50 pilgrims during last year's haj season," he said. He also praised the dedication, patience, and sincerity of the companions in fulfilling their duty to assist this high-risk group of pilgrims. Zaimah Abdul Majid, 60, whose mobility is restricted due to her swollen legs, appreciated the TH initiative in providing dedicated assistance for pilgrims in need of extra support.
BusinessToday
8 hours ago
- BusinessToday
No Wires, No Limits: A Bold Leap in Cardiac Tech
Institut Jantung Negara (IJN) has made history with a medical first for Southeast Asia. The team successfully implanted the Abbott AVEIR™ DR, the world's first dual-chamber leadless pacemaker. Approved by the US Food and Drug Administration (FDA) in 2023, this device is a game-changer for individuals with heart rhythm disorders. 'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN. 'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.' Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle. At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems. 'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.' At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine. Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes. Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove. As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs. As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted. As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
